Opdivo Gets A Melanoma Rejection, But Also An Expansion

A drug that looked like it could do no wrong in the FDA's eyes, Bristol-Myers Squibb Co.'s Opdivo (nivolumab), actually got a rejection from the agency to expand the medicine's use as a single agent for previously untreated patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

A drug that looked like it could do no wrong in the FDA's eyes, Bristol-Myers Squibb Co.'s Opdivo (nivolumab), actually got a rejection from the agency to expand the medicine's use as a single agent for previously untreated patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

But the FDA last week also awarded the medicine its sixth indication in less than 12 months as a single...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category